Stellaromics Inc.

United States - Natick, Massachusetts

• 03/11/2023
• Series A
• $25,000,000

Founded in 2022 and headquartered in Boston, Stellaromics is revolutionizing biomedical research with its proprietary technology, unraveling complex 3D transcription and translation patterns within native biological tissue. At the forefront of their innovation is STARmap (Spatially-resolved Transcript Amplicon Readout mapping), their flagship product. STARmap empowers researchers to uncover gene expression patterns within intact tissue, facilitating the pinpointing of treatment targets and bolstering biomedical investigations.

Stellaromics is currently in the advanced stages of developing its Plexa™ suite of products, meticulously crafted to empower researchers and clinicians in the creation of intricate cellular maps, thereby amplifying our comprehension of various diseases.

For comprehensive details, we invite you to explore our website at stellaromics.com. Join us in shaping the future of biomedical research.

Related People

Todd DickinsonFounder

United States - Boston, Massachusetts

I'm a dedicated life sciences executive with a strong commitment to creating purpose-driven organizations that catalyze advancements in human health. I am deeply grateful for the opportunities I’ve had over the last 20 years to help build transformational companies. I am driven to do good, and to build things that really matter. Along the way I have learned that no matter how good your technology or business plan might be, it’s the people that truly make a company successful. I count the relationships I’ve made along my journey, with both colleagues and customers, at Illumina, Bionano Genomics, Dovetail, Arc Bio, and Cantata Bio, as some of the most meaningful connections in my life. I am thrilled to start a new venture with the extraordinary team at Stellaromics, and can’t wait to leave our impact on the world!

LinkedIn https://www.linkedin.com/in/todd-dickinson-2296b822/